13819 studies found for:    Open Studies | "Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Conditions: Breast Cancer;   Lung Cancer;   Renal Cancer;   Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
22 Recruiting Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12
Conditions: Breast Cancer;   Colorectal Cancer;   Lung Cancer;   Melanoma (Skin);   Pancreatic Cancer
Intervention:
23 Not yet recruiting Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: selumetinib;   Drug: cyclosporine;   Other: laboratory biomarker analysis;   Other: pharmacological study
24 Recruiting A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Condition: Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
Interventions: Drug: BYL719;   Drug: Paclitaxel
25 Recruiting Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: mifepristone;   Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
26 Unknown  Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Conditions: Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review;   Other: study of socioeconomic and demographic variables;   Procedure: disease screening;   Procedure: evaluation of cancer risk factors;   Procedure: genitourinary surgical procedure;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
27 Recruiting Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Conditions: Adenocarcinoma of the Lung;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Squamous Cell Lung Cancer;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Colon Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer
Interventions: Other: educational intervention;   Other: medical chart review
28 Recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, Peritoneal Cancer, or Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Triple-negative Breast Cancer
Interventions: Drug: olaparib;   Drug: cediranib maleate;   Other: laboratory biomarker analysis
29 Recruiting A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Conditions: Neoplasms;   Neoplasm Metastasis;   Pancreatic Cancer
Interventions: Drug: LY2157299;   Drug: Gemcitabine;   Drug: Placebo
30 Recruiting Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Conditions: Breast Cancer;   Bladder Cancer;   Kidney Cancer;   Colon Cancer;   Prostate Cancer;   Lung Cancer
Intervention: Genetic: PCR/PCR/LDR Strategy
31 Recruiting Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage II Vaginal Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Vaginal Cancer;   Stage IIIA Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma
Interventions: Drug: triapine;   Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Other: laboratory biomarker analysis
32 Recruiting Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Conditions: Head and Neck Cancer;   Lung Cancer;   Lip Cancer;   Lip Neoplasms;   Head and Neck Cancers
Interventions: Procedure: Tumor biopsy;   Procedure: Phlebotomy
33 Recruiting Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Metastatic Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
34 Recruiting Mithramycin for Lung, Esophagus, and Other Chest Cancers
Conditions: Lung Cancer;   Esophageal Cancer;   Mesothelioma;   Gastrointestinal Neoplasms;   Breast Cancer
Intervention: Drug: Mithramycin
35 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Breast Cancer;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Bladder Cancer
Intervention: Drug: IMMU-132
36 Unknown  Questionnaire Study for Gynecological Cancer Survivors
Conditions: Endometrial Neoplasms;   Ovarian Neoplasms;   Uterine Cervical Neoplasms;   Vulvar Neoplasms;   Vaginal Neoplasms;   Genital Neoplasms, Female
Intervention: Behavioral: Psychosocial
37 Recruiting Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Conditions: Colorectal Neoplasms;   Gastric Neoplasms;   Cholangiocarcinoma;   Bile Duct Cancer;   Pancreas Cancer
Intervention:
38 Recruiting Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer
Conditions: Lymphedema;   Stage IA Cervical Cancer;   Stage IA Endometrial Carcinoma;   Stage IA Vulvar Cancer;   Stage IB Cervical Cancer;   Stage IB Endometrial Carcinoma;   Stage IB Vulvar Cancer;   Stage II Endometrial Carcinoma;   Stage II Vulvar Cancer;   Stage IIA Cervical Cancer;   Stage IIIA Vulvar Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVB Vulvar Cancer
Interventions: Procedure: therapeutic lymphadenectomy;   Procedure: therapeutic conventional surgery;   Procedure: therapeutic laparoscopic surgery;   Procedure: study of high risk factors;   Other: questionnaire administration;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
39 Recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: hydroxychloroquine;   Other: pharmacological study;   Other: laboratory biomarker analysis
40 Recruiting Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: veliparib;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years